Versartis Inc (VSAR) was Initiated by Piper Jaffray to “Overweight”. Piper Jaffray advised their investors in a research report released on Oct 4, 2016.
On the company’s financial health, Versartis Inc reported $-0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Oct 29, 2015. Analyst had a consensus of $-0.79.During the same quarter in the previous year, the company posted $-0.57 EPS.
Versartis Inc opened for trading at $12.18 and hit $12.36 on the upside on Friday, eventually ending the session at $12.25, with a gain of 0.82% or 0.1 points. The heightened volatility saw the trading volume jump to 3,46,266 shares. Company has a market cap of $362 M.
In a different news, on Aug 24, 2016, Jay Shepard (President and CEO) sold 5,442 shares at $12.88 per share price. According to the SEC, on Jun 17, 2016, Joshua T Brumm (Chief Financial Officer) sold 1,448 shares at $10.63 per share price. On Jun 17, 2016, Paul Westberg (Sr. VP, Business Development) sold 725 shares at $10.63 per share price, according to the Form-4 filing with the securities and exchange commission.
Versartis Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone VRS-317 for growth hormone deficiency (GHD) an orphan disease. The Company’s products include VRS-317 and XTEN Technology. VRS-317 combines the rhGH amino acid sequence utilized in rhGH products with a half-life extension technology XTEN to enable less frequent administration. The Company has initiated a Phase III clinical study of VRS-317 in pediatric growth hormone deficient patients. XTEN is a recombinant polypeptide that when genetically fused to a therapeutic payload of interest extends the in vivo half-life of these peptides and proteins in a tunable manner.